Premium
A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic‐clonic epilepsy
Author(s) -
Rane C. T.,
Dalvi S. S.,
Gogtay N. J.,
Shah P. U.,
Kshirsagar N. A.
Publication year - 2001
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.0306-5251.2001.01436.x
Subject(s) - medicine , epilepsy , therapeutic drug monitoring , confidence interval , adverse effect , pediatrics , retrospective cohort study , drug , emergency medicine , intensive care medicine , pharmacology , psychiatry
Aims To carry out a retrospective pharmacoeconomic analysis of the impact of therapeutic drug monitoring (TDM) in adult patients with generalized tonic‐clonic epilepsy in an academic, non profit making organization. Methods Twenty‐five patients who had undergone TDM were compared with 25 age, disease and duration of drug therapy matched controls who had not undergone TDM. Only direct costs were calculated. These included cost to the hospital of providing the TDM service, cost to the hospital per seizure saved, and cost to the patient per seizure saved. Results Patients undergoing TDM had much more effective seizure control (P = 0.00032, OR 4.846, 95% confidence interval 1.29,18.3), fewer adverse events, better earning and were more likely to be married than the control group. Conclusions In patients with adult onset epilepsy, a minimum of two drug estimations per year offers significant benefit in terms of better seizure control, fewer adverse events and greater chances of remission.